CLN Article

Multicancer (early) detection tests at a glance  

Ask the Expert 

Stefani Thomas, PhD, DABCC, NRCC

What are MCEDs?

In the United States, >70% of cancer deaths arise from cancers without established screening strategies. Multicancer early detection (MCED) tests aim to address this gap by using a blood sample to detect signals associated with up to 50 cancer types.  

MCEDs analyze tumor-derived biomarkers circulating in blood, such as cell-free DNA, circulating tumor DNA, cell-free RNA, and proteins. Technologies used include whole-genome sequencing, next-generation sequencing, reverse transcription PCR, immunoassays, and mass spectrometry. Several companies to date have advanced MCED technologies through late-stage biomarker development programs.  

Despite the promise of MCEDs, evidence remains limited that these tests consistently detect early-stage cancers at sufficiently high rates or reduce cancer-specific mortality. Consequently, some experts argue that these assays are more accurately described as multicancer detection rather than multicancer early detection tests.

How well do MCEDs perform?

MCED performance varies substantially by cancer type. In general, these tests perform best for cancers that lack effective screening guidelines and less well for cancers already targeted by established screening programs. MCEDs are intended to complement, not replace, existing screening approaches.  

To minimize unnecessary diagnostic evaluations performed because of false-positive results, most MCED tests are designed with very high specificity. For example, the recent PATHFINDER 2 prospective study of >35,000 participants reported that Grail’s Galleri MCED test had a positive predictive value of 60.3%, negative predictive value of 99.2%, specificity of 99.6%, and episode sensitivity of 39.3%.  

What are the risks of MCEDs?

A major concern is false reassurance. A negative result does not exclude cancer and could lead some patients to delay evaluation of their symptoms or forgo recommended standard-of-care screening tests. Conversely, positive results may trigger follow up procedures that expose patients to radiation and other risks, anxiety, and healthcare costs. Even true-positive findings can cause harm through overtreatment of a cancer that might never have become clinically significant. Additional unresolved issues include determining optimal screening intervals and ensuring appropriate follow-up pathways.

Are any MCEDs FDA-approved?

At present, no MCED test has full Food and Drug Administration (FDA) authorization specifically for population-based screening of multiple cancers. However, on September 23, an FDA advisory committee voted in favor of the premarket approval application for Grail’s Galleri MCED test in adults aged 50 and older. Although the panel unanimously supported the test’s safety and concluded that its benefits outweigh its risks, the narrow vote on effectiveness reflected continued caution and debate regarding the test’s clinical utility.  

How could MCEDs impact healthcare delivery in the future?  

As the regulatory and health insurance coverage landscape surrounding MCEDs evolves, clinical adoption of MCEDs will likely expand. Broader adoption depends on generating evidence that the benefits of MCEDs outweigh potential harms. The Cancer Screening Research Network recently launched the Vanguard study, the first U.S. randomized trial of MCEDs, to inform the design of larger studies evaluating whether MCED screening reduces cancer mortality.  

If proven effective, MCEDs could substantially expand access to cancer screening. Unlike current approaches that often require time-consuming procedures to screen for individual cancers, MCEDs can evaluate multiple cancers simultaneously from a blood draw obtained during routine healthcare visits. This convenience may help to improve participation among underserved populations.  

Stefani Thomas, PhD, DABCC, NRCC, is an assistant professor of laboratory medicine and pathology at the University of Minnesota and associate medical director of the M Health Fairview West Bank Laboratories. +Email: [email protected]

Read the full November-December issue of CLN.

Advertisement

Advertisement